Sun Pharma Recalls 10 Ophthalmic Eye Drop Products Over Quality Issue

Leading Indian pharmaceutical manufacturer Sun Pharma initiated a nationwide voluntary market recall of 10 ophthalmic eye drop products due to potential contamination risks. The company stated the preventive measure was taken in compliance with Good Manufacturing Practices (GMP) and national drug safety regulations.

India's pharmaceutical domain is regulated under the Drugs and Cosmetics Act, 1940, and governed by the Central Drugs Standard Control Organization (CDSCO) led by the Drugs Controller General of India (DCGI).

The recall affects specific commercial batches across multiple distribution networks. Standard operating protocols mandate batch tracing, root-cause investigation, and formal reporting to CDSCO regulators.

Regulatory mechanisms governing India's pharmaceutical industry, drug safety protocols, and CDSCO functions represent key topics in UPSC GS Paper III (Technology & Industry) and healthcare awareness sections.